CN113767103A - 新型螺环类K-Ras G12C抑制剂 - Google Patents

新型螺环类K-Ras G12C抑制剂 Download PDF

Info

Publication number
CN113767103A
CN113767103A CN202080029934.1A CN202080029934A CN113767103A CN 113767103 A CN113767103 A CN 113767103A CN 202080029934 A CN202080029934 A CN 202080029934A CN 113767103 A CN113767103 A CN 113767103A
Authority
CN
China
Prior art keywords
substituted
alkyl
halogen
general formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080029934.1A
Other languages
English (en)
Other versions
CN113767103B (zh
Inventor
谢雨礼
樊后兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN113767103A publication Critical patent/CN113767103A/zh
Application granted granted Critical
Publication of CN113767103B publication Critical patent/CN113767103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类螺环类化合物及其制备方法和用途。具体地，本发明涉及式(1)所示的化合物及其制备方法，以及式(1)化合物及其各光学异构体、各晶型、药学上可接受的盐作为G12C突变体K‑Ras蛋白不可逆抑制剂在抗肿瘤等Ras相关疾病的药物制备中的用途。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080029934.1A 2019-08-15 2020-08-14 新型螺环类K-Ras G12C抑制剂 Active CN113767103B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910756965.6A CN112390797A (zh) 2019-08-15 2019-08-15 新型螺环类K-Ras G12C抑制剂
CN2019107569656 2019-08-15
PCT/CN2020/109099 WO2021027911A1 (zh) 2019-08-15 2020-08-14 新型螺环类K-Ras G12C抑制剂

Publications (2)

Publication Number Publication Date
CN113767103A true CN113767103A (zh) 2021-12-07
CN113767103B CN113767103B (zh) 2024-03-29

Family

ID=74570474

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910756965.6A Pending CN112390797A (zh) 2019-08-15 2019-08-15 新型螺环类K-Ras G12C抑制剂
CN202080029934.1A Active CN113767103B (zh) 2019-08-15 2020-08-14 新型螺环类K-Ras G12C抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910756965.6A Pending CN112390797A (zh) 2019-08-15 2019-08-15 新型螺环类K-Ras G12C抑制剂

Country Status (2)

Country Link
CN (2) CN112390797A (zh)
WO (1) WO2021027911A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017266911B2 (en) * 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es) * 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019099524A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN112047937B (zh) * 2019-06-06 2023-04-07 劲方医药科技(上海)有限公司 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途

Also Published As

Publication number Publication date
WO2021027911A1 (zh) 2021-02-18
CN113767103B (zh) 2024-03-29
CN112390797A (zh) 2021-02-23

Similar Documents

Publication Publication Date Title
CN113767103A (zh) 新型螺环类K-Ras G12C抑制剂
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
CN113544128B (zh) Kras-g12c抑制剂
EP4083042A1 (en) Spiro ring-containing quinazoline compound
CN115335379B (zh) 含螺环的喹唑啉化合物
CN112312904A (zh) 螺环化合物
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN111386275B (zh) 高活性sting蛋白激动剂
CN115315427A (zh) Hpk1抑制剂及其制备方法和用途
EP3388433B1 (en) Phthalazine derivatives, and preparation method, pharmaceutical composition and use thereof
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
US20120108600A1 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
CN113045570A (zh) 含螺环的喹唑啉化合物
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN107428762B (zh) 酞嗪酮衍生物、其制备方法及用途
CN112513041B (zh) 三环化合物
CN113754659A (zh) 含螺环的喹唑啉化合物
KR20220068224A (ko) Perk 억제 화합물
WO2021244505A1 (zh) 新型吡嗪化合物
CN113880804A (zh) 新型苯并咪唑化合物
WO2024099225A1 (zh) Ulk抑制剂
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
WO2022188889A1 (zh) 作为parp7抑制剂的化合物
TW202306955A (zh) 作為atr抑制劑的萘啶衍生物及其製備方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant